Solaris DE Covered Stent for Dialysis Access Evaluated in 6-Month DEScover Data

September 8, 2026—Solaris Endovascular, Inc. announced complete 6-month results from the DEScover study evaluating the company’s investigational Solaris DE sirolimus-eluting covered stent for dialysis access dysfunction.

Medtronic’s Endurant Stent Graft System Receives Updated Ruptured AAA Labeling in Europe

September 4, 2026—Medtronic announced it has received CE Mark approval for the Endurant stent graft system to remove the ruptured abdominal aortic aneurysms (rAAA) treatment warning.

CMS NTAP Granted for Reflow Medical Spur Peripheral Retrievable Stent System

September 2, 2026—Reflow Medical, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for the company’s Spur peripheral retrievable stent system, providing additional reimbursement for eligible fee-for-service Medicare inpatient cases beginning October 1, 2026.

Canadian Enrollment Begins in B-SILENT Study of Sonorous’s BosStent Cerebral Venous Stent

September 2, 2026—Sonorous Neurovascular announced the commencement of enrollment at Canadian sites in the B-SILENT clinical study of the company’s investigational BosStent.

Shockwave Medical to Rebrand as Johnson & Johnson MedTech

September 1, 2026—Shockwave Medical announced on the company’s LinkedIn page that it will be rebranded as Johnson & Johnson MedTech with Shockwave’s technologies to be known as “circulatory restoration solutions,” effective October 1, 2026.

TRUST Pivotal Study of Innova Laguna Thrombectomy System Completes Enrollment

September 1, 2026—Innova Vascular, Inc. announced the completion of patient enrollment in the TRUST pivotal investigational device exemption clinical study, which is evaluating the safety and effectiveness of the company’s Laguna thrombectomy system for the treatment of pulmonary embolism (PE).

Terumo Neuro WEB Evaluated in Ruptured and Unruptured Aneurysm Cohorts

September 1, 2026—Terumo Neuro, a wholly owned subsidiary of Terumo Corporation, announced two separate peer-reviewed publications reporting 1-year outcomes from the WISE study of the Woven EndoBridge (WEB) implant’s safety and long-term efficacy.

Abbott’s 76-mm Esprit BTK System for CLTI Approved in Europe

August 28, 2026—Abbott announced it has received CE Mark approval for its longer-length (76-mm) Esprit below-the-knee (BTK) system for the treatment of chronic limb-threatening ischemia (CLTI).